The company attributed the revenue decline to the conclusion of agreements with licensing partners for the sale of its products.
The revenue increase was driven by a 41 percent rise in product sales.
The company has agreed to a takeover bid that values it at roughly €171 million ($186.3 million).
VA patients will now have access to Polymedco's colorectal cancer screening products, including the Epigenomics Epi proColon.
The qPCR-based test was shown to differentiate cancerous and non-cancerous tissue and predict biochemical recurrence, and can be used on small, degraded samples.
The revenue increase was driven by increased sales of Epigenomics recently approved colorectal cancer screening test Epi proColon.
Two researchers, who have both received grants from Epigenomics, noted in a JAMA letter that the USPSTF did not use data on the FDA-approved version of the test.
The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.
The company said orders are increasing for its blood-based colorectal cancer screening test Epi proColon, which has been rolled out in Europe, China, and the US.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.